Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Technical Analysts See Bullish Signs for Biotech ETFs

6/06/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzkvmdivndi2l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

After a sharp sell-off in March and languish trading through May, the biotechnology sector and related exchange traded funds are looking to break out.

The iShares Nasdaq Biotechnology ETF, which tracks biotech and pharma stocks on the Nasdaq, fell 9.6% over the past three months, but the ETF is up 1.6% over the past week and 6.3% higher over the last month. Last week, IBB broke above its 50-day moving average.

Ed Ponsi, managing direction of Barchetta Capital Mangement, pointed out that IBB’s break above its short-term resistance level, the first time since March, was a bullish indicator, reports Lee Brodie for CNBC.

Furthermore, Ponsi noted that IBB broke out of a symmetrical triangle pattern that has formed for weeks. The symmetrical triangle pattern is recognized by its distinct triangle shape formed by two converging trendlines that connect recent peaks and troughs.

IBB’s symmetrical triangle pattern showed its trendlines converged around $231 per share – IBB currently trades around $245 per share. The two trendlines act as barriers on prices increases and decreases, but when the price breaches one of these lines, a sharp move typically follows. Currently, the ETF is breaking out on the bullish side.

Looking at individual picks, Ponsi argued that biotech firms like Celgene and big pharma Regeneron are also showing bullish chart patterns.

“That would mean the monster sell-off has created some terrific buying opportunities,” Mad Money’s Cramer noted in the article. “I think Ponsi is dead right.”

This article has been extracted from http://www.etftrends.com, please click on this link to read the article in full http://www.etftrends.com/2014/06/technical-analysts-see-bullish-signs-for-biotech-etfs/

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdgvmtqvmtmvmjcvmjgvnja2l2nsb3rozxmuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

In Her Shoes... From Market Stall to Recruitment

2017-08-14 14:00:00 +0100

From the melee of the market stall to placing candidates in high-flying IT roles, life's always on the up from market-trader-turned-recruiter, Lois Hinken (22). She took the time to talk to us about how her experience in the cut throat world of the market has helped her in the world of global talent acquisition. As a 360 recruitment consultant for Montash, her negotiation skills and "go get it" attitude have helped her thrive. "I started working on the ...

W1siziisijiwmtcvmdgvmdcvmtmvmtcvntqvnze3l1vudgl0bgvkigrlc2lnbiaomikuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

Will AI Cost Us Our Humanity?

2017-08-07 15:00:00 +0100

As technology evolves, artificial intelligence is becoming increasingly mainstream, and it will inevitably start to impact the way we interact. On the one hand, AI has the potential to solve a variety of problems and streamline our lives and our work. But will this come at the cost of the all-important human touch? A foreshadowing statistic claims that by 2020, 85% of client interactions will be managed without a human[1]. But can there really be an alg...